Stella Pharma Corporation (TYO:4888)
Japan · Delayed Price · Currency is JPY 881.00
+103.00 (13.24%)
At close: Mar 27, 2026
Stella Pharma Revenue
Stella Pharma had revenue of 61.00M JPY in the quarter ending December 31, 2025, a decrease of -28.24%. This brings the company's revenue in the last twelve months to 968.00M, up 199.69% year-over-year. In the fiscal year ending March 31, 2025, Stella Pharma had annual revenue of 961.00M with 257.25% growth.
Revenue (ttm)
968.00M
Revenue Growth
+199.69%
P/S Ratio
30.98
Revenue / Employee
22.51M
Employees
43
Market Cap
29.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 961.00M | 692.00M | 257.25% |
| Mar 31, 2024 | 269.00M | 40.00M | 17.47% |
| Mar 31, 2023 | 229.00M | 129.00M | 129.00% |
| Mar 31, 2022 | 100.00M | -105.00M | -51.22% |
| Mar 31, 2021 | 205.00M | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.98B |
| ReproCELL | 2.52B |
| Japan Tissue Engineering | 2.26B |
| Immuno-Biological Laboratories | 1.03B |
| AnGes | 874.00M |
| Cuorips | 356.00M |
| Renascience | 107.00M |
| Healios K.K. | 104.00M |